Duration
This Phase 3 study is evaluating whether an investigational drug called nipocalimab can safely and effectively reduce symptoms in adults with moderate to severe Sjögren’s disease.
Participants are randomly assigned to receive either nipocalimab or a placebo. The study is conducted at multiple sites and is fully blinded — neither participants nor study staff know who is receiving the active drug.
Condition: Sjögren’s Disease
Learn more: View on ClinicalTrials.gov
This is completely confidential, your answers are processed locally and are not stored or transmitted. Only your contact information is saved if you choose to submit it.
We have several clinical trials and you may be eligible for more than one. Lets find out.
This Phase 4 study is enrolling adults with early polymyalgia rheumatica...
This study tested whether adding an investigational drug called Natrunix to...
This study tested a new molecular tool (called a “response classifier”)...
This open-label, long-term extension study allowed patients who had already completed...
This open-label study (meaning all participants knew which treatment they received)...
This study evaluated whether an investigational drug called D-0120, taken together...
This study tested whether an investigational drug called LY3871801 is safe...
This study collected blood samples from adults with rheumatoid arthritis (RA)...
This open-label Phase 2 study is currently enrolling adults with uncontrolled...
This multicenter study is evaluating the effectiveness and safety of an...
This Phase 2 study is examining whether an investigational drug called...
This Phase 3 study is testing whether an investigational drug called...
